Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 4(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02623504Phase 4Terminated

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

Role: lead

NCT00350857Phase 4Completed

The Young Adult and Pediatric Bipolar Study

Role: lead

NCT00150605Phase 3Completed

Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder

Role: lead

NCT00150553Phase 3Completed

Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder

Role: lead

All 4 trials loaded